A Phase II Study of Suberoylanilide Hydroxamic Acid and Bortezomib in Advanced Soft Tissue Sarcomas.
Phase of Trial: Phase II
Latest Information Update: 20 Nov 2013
At a glance
- Drugs Bortezomib (Primary) ; Vorinostat (Primary)
- Indications Soft tissue sarcoma
- Focus Therapeutic Use
- 06 Dec 2012 Planned end date changed from 1 Aug 2010 to 1 Jun 2013 as reported by ClinicalTrials.gov.
- 09 Nov 2012 Primary endpoint and lead trial centre amended as reported by ClinicalTrials.gov.
- 01 Jun 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.